NCT00104455已完成1 期
Recombinant Activated Factor VII (rFVIIa/NovoSeven) Dose Response Trial in Healthy Volunteers: A Double-Blind, Placebo-Controlled, Cross-over, Dose-Escalation Trial to Investigate the Dose Response to REcombinant Factor VIIa When Administered for Bleeding Following Punch Biopsies in Healthy Volunteers
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 64
- 试验地点
- 2
- 主要终点
- Dose Response to Recombinant Factor VIIa
研究概览
简要总结
This trial is conducted in the United States of America (USA). The purpose of this trial is to investigate the dose response to recombinant factor VIIa in healthy volunteers when administered for bleed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Ages Eligible for Study: 18 Years - 60 Years
排除标准
- 未提供
结局指标
主要结局
Dose Response to Recombinant Factor VIIa
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Use of Activated Recombinant FVII in Spinal SurgeryAcquired Bleeding DisorderSpinal FusionNCT00102037Novo Nordisk A/S50
已完成
1 期
Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin TreatmentHaemostasisHealthyNCT01561937Novo Nordisk A/S127
终止
1 期
Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated BleedingHaemostasisHealthyNCT01561950Novo Nordisk A/S91
Unknown
3 期
"Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac SurgeryBlood Coagulation DisordersHeart Valve DiseasesCoronary Artery DiseaseMyocardial IschemiaNCT00214656Austin Health40
已完成
不适用
Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains MalaysiaMassive HemorrhageMassive Blood LossMassive Blood Transfusion ThrombocytopeniaNCT03251547Universiti Sains Malaysia76